Enclomiphene vs Clomiphene: What's Actually Different?

Enclomiphene vs clomiphene comes down to evidence, product status, and your diagnosis—not a proven winner. Clomiphene contains two geometric isomers; enclomiphene isolates one. Limited comparative studies do not establish enclomiphene as more effective or safer overall. Clomiphene has FDA-approved products, but male use is off-label; enclomiphene has none. Fertility plans change the decision.¹²³¹⁶

Last verified: September 2026 · Checked September 21, 2026 · By TRT Provider Guide · Educational information, not medical advice

Best for: U.S. adult men comparing clinician-supervised selective estrogen receptor modulator (SERM) options after a low-testosterone or fertility evaluation. Not a treatment selector: unexplained abnormal labs, current infertility, or a possible pituitary or testicular disorder need clinical evaluation first.⁶⁸

Enclomiphene vs clomiphene: what’s the bottom line?

The composition difference is real; a universal clinical winner is not established. The useful comparison separates testosterone results, side effects, fertility, product approval, and the full cost of care.¹²³

So the real question in "enclomiphene vs clomiphene" isn’t just what’s the difference. The real question is whether that difference shows up in actual patients.

That’s messier than the marketing. We’ll separate the results we could verify in full from a conference report whose detailed data we could not inspect.

Clomiphene may be a discussion point if…

• Your clinician has established a reason to consider a SERM—a selective estrogen receptor modulator
• You want an FDA-approved commercial drug product rather than a compounded preparation
• Cost matters and you have a clinician willing to prescribe and monitor it
• You want an option with a longer history of use in men, while understanding that male treatment is off-label¹⁸

Enclomiphene may be worth discussing if…

• Clomiphene gave you side effects you could feel—such as low mood or reduced libido—and you want to discuss alternatives
• Your clinician agrees the isolated molecule merits consideration and you understand the compounded-product tradeoff
• You have a written quote for the exact product and the full care plan, not just a starting pill price³¹¹

Clinical evaluation comes before choosing either if…

• Your hormone results suggest a pituitary or testicular problem
• You and your partner are trying to conceive right now—that’s a urologist or reproductive-urologist conversation
• You compete under anti-doping rules or serve in the military and need the relevant medical and rules review
• Nobody has confirmed you actually have low testosterone yet⁶⁸¹⁶¹⁸

---

The right TRT provider is not the same for every person — it depends on whether low testosterone has been properly evaluated, your symptoms and health history, your fertility plans, your state, your insurance or cash-pay preference, your treatment-format preference, your budget, and whether online or in-person care is the better starting point. Some situations belong with primary care, urology, endocrinology, reproductive urology, or urgent or emergency care when the symptoms warrant it. Because a general answer cannot resolve those for you, use TRT Provider Guide's Find My TRT Path tool to map your situation to the right care route and the questions to ask before you pay.

TRT Provider Guide is the independent decision resource for testosterone replacement therapy — helping U.S. adults understand how low testosterone is evaluated, compare online and local care models and providers, and choose the next step that fits their health needs, fertility plans, budget, state, and care preferences, with every material claim verified and dated.

---

Is enclomiphene better than clomiphene?

There is not enough evidence to say enclomiphene is better than clomiphene for most men. The two full comparative reports reviewed here are retrospective; neither established superior testosterone improvement with enclomiphene, and only one directly compared adverse effects. No randomized head-to-head trial establishing overall superiority was identified in this review.²³⁵

That’s the central finding. Now here’s the evidence it comes from.

We checked the Thomas 2023 and Saffati 2024 full reports, including their tables and limitations. We also located the publication record for Kassab’s 2023 pregnancy comparison, MP43-13, but could not retrieve its full results for this check. It remains in the evidence map below; unverified numerical results from that abstract do not drive our verdict.²³⁴

The direct-comparison evidence map

Sources: Thomas and colleagues, Tables 1–6; Saffati and colleagues, Tables 1–4; Kassab and colleagues, publication record.²³⁴

The Thomas report’s lab and outcome denominators vary, and the Saffati adverse-effect percentages also need caution. We preserve the authors’ reported figures rather than silently treating them as results from every enrolled patient. The Thomas study’s 300 ng/dL research threshold is not a diagnosis by itself.²³⁶

Total motile sperm count is the number of moving sperm in an ejaculate — one of the numbers a fertility clinic actually cares about.

What this actually tells you

On testosterone, these full reports do not establish enclomiphene as the winner. Both found no statistically significant difference in improvement between treatments. “Not significant” is not proof of equal effects; small retrospective studies can miss real differences.²³

Be careful with those comparisons, though. They are retrospective looks at clinical records, not randomized trials. Dose, patient selection, timing, and why a doctor picked or changed a drug could affect the result. They do not establish that either drug is inherently stronger.²³

On estrogen, a blood level is not the same as a side effect. The Baylor switch study found lower estradiol during enclomiphene treatment. In the Miami study, enclomiphene rose significantly from its own baseline—but the direct comparison of estradiol changes between drugs was not significant. That does not establish clomiphene as the better-tolerated drug in that study.²³

And here’s the point that should reframe how you think about all of this. Neither a higher testosterone result nor a better semen result proves that a treatment will improve symptoms or lead to pregnancy. Those outcomes need to be measured, not assumed.⁹

A higher testosterone number is not the goal. Feeling better and meeting your actual goal is the goal. Any provider who sells you on the lab value alone is selling you the scoreboard, not the game.

Sorting real evidence from good marketing

We use four plain labels throughout this page so you can see how much weight each claim can carry:

Here's where the common claims land:

The honest summary: enclomiphene’s chemistry is cleaner than its evidence. “Cleaner” here means one isomer rather than a two-isomer mixture—not purer manufacturing, fewer risks, or proven better results.¹³

Still not sure which lane you're in?

Everything below depends on facts about you — your labs, your fertility plans, your state, your budget. There's no version of this article that can answer those.

Map your situation with Find My TRT Path → A free, non-diagnostic tool that walks you through which care route fits and what to ask before you pay. It won't tell you that you have low testosterone, and it won't get you a prescription.

---

What is the actual difference between enclomiphene and clomiphene?

Clomiphene citrate contains two geometric isomers—different arrangements of the same atoms around a double bond, not mirror-image molecules. Enclomiphene is one of those isomers; zuclomiphene is the other and persists longer in the body. Enclomiphene treatment isolates the first component.¹

Think of clomiphene as a package holding two closely related molecules. Enclomiphene is one of them, taken out and used on its own.

The FDA-approved Clomid label states that clomiphene citrate is a mixture of two geometric isomers and contains between 30% and 50% of the cis-isomer — that's zuclomiphene.¹

The two components behave differently:

Enclomiphene reduces estrogen’s feedback signal at the hypothalamus and pituitary—the hormone-control system in your brain. That can increase luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH tells the testicles to make testosterone. FSH supports sperm production. FDA’s review describes an enclomiphene half-life of roughly 10 hours; a half-life is not the time it takes the drug or its effects to clear completely.⁹

Zuclomiphene has greater estrogen-like activity in some experimental data and remains detectable much longer. The Clomid label reports detectable zuclomiphene for longer than a month after a single dose; it does not establish a universal 30-day half-life.¹

That’s the pharmacologic case for isolating enclomiphene: remove the longer-lasting component while retaining the desired hormone response. Whether that also reduces side effects or improves patient outcomes is the part that needs clinical proof.

It’s a plausible idea. It’s also a hypothesis about a mechanism, not a demonstrated overall patient advantage. The comparative studies above are where that hypothesis meets reality, and the evidence remains limited.²³

So is enclomiphene just "purified Clomid"? As shorthand for isolating one component, it captures part of the chemistry. As a claim about finished medicines, no. Removing zuclomiphene changes the drug’s behavior. It does not automatically produce better results—and a compounded enclomiphene product does not have the approval of an FDA-approved clomiphene product.¹¹¹

---

Which one raises testosterone more?

Neither has been shown to raise testosterone more than the other in a randomized head-to-head trial identified in this review. The two full direct comparisons reviewed here found no statistically significant difference in testosterone improvement. Both act through hormone signaling that can increase the body’s own testosterone production in responsive men.²³⁵

If you only remember one thing from this section, make it this: **the evidence reviewed here does not establish that enclomiphene raises testosterone better than clomiphene.**²³

What we do know about the class as a whole is stronger. A 2025 systematic review and meta-analysis included 10 randomized controlled trials covering 819 men. In the placebo comparisons, SERM treatment raised total testosterone by an average of about 274 ng/dL (95% confidence interval 192–356). LH and FSH went up too. The trials focused on functional hypogonadism, and the results varied substantially between studies.⁵

And one more result from that analysis: there was no significant difference in testosterone between the SERM group and men using testosterone gel. That is a laboratory comparison, not proof of equal symptom relief, fertility outcomes, or long-term safety.⁵

Here’s the detail that matters most for your question, though. That meta-analysis pooled clomiphene and enclomiphene together as a drug class. It was not a randomized comparison of one against the other.⁵

Pooling can answer a class-level question. It cannot establish that the two medicines are interchangeable or that one is superior. Follow-up in the included trials ranged from 2 to 30 weeks, so the analysis also does not settle long-term safety.⁵

Total testosterone is the total amount of testosterone in your blood, including the portion bound to proteins. It's also only one input. Symptoms, the cause of your low testosterone, your fertility goals, side effects, and whether you'll actually stay on the medication all matter more than which drug wins by 50 ng/dL on a chart.

---

Does enclomiphene cause fewer side effects than clomiphene?

One retrospective study suggests fewer reported side effects on enclomiphene, but that is not proof that it is safer overall. The report included 66 men who took clomiphene and later switched to enclomiphene, with adverse-effect percentages reported as 47% versus 13.8%. The denominators and unequal follow-up periods limit how literally to read that difference.³

The Baylor switch study provides the direct adverse-effect comparison used here. These are its reported counts and percentages—not your personal risk of a side effect.³

Source: Saffati and colleagues, Table 3, reproduced as reported.³ See the enclomiphene vs clomiphene side-effect numbers.

A denominator problem worth seeing: 31/66 is about 47%, but 8/66 is about 12.1%, not 13.8%. The enclomiphene counts and percentages in Table 3 are consistent with a denominator of 58, while the paper describes a 66-man cohort. The text does not clearly resolve that discrepancy. We have not silently recalculated the study’s rates or treated them as a clean same-denominator risk comparison.

The reported odds ratio for any adverse event was 0.18 (95% confidence interval 0.07–0.44): about 82% lower odds, not an 82% reduction in the probability of a side effect. That is the study’s statistical association, not a guaranteed effect of switching.³

That's a real signal and we're not going to soften it. If clomiphene made you feel flat, this table is a reason to discuss alternatives with your prescriber—not a reason to change treatment yourself.

Why the number is less clean than it looks

The study authors flag three limits themselves: it was retrospective, done at one center, and there was no washout period between the drugs. Since zuclomiphene can remain detectable for over a month, carryover could affect measurements during the switch. The enclomiphene baseline also followed clomiphene treatment rather than an untreated baseline.³¹

There's a fourth thing the paper reports but doesn't discuss, and we think it matters. Men were on clomiphene for a median of 18.7 months and on enclomiphene for a median of 8.9 months. They were watched on the first drug for more than twice as long as the second, and side effects were counted from clinic notes over those windows. A longer window is a longer chance to record something. That's our reading of their published numbers, not a claim the authors made — but the two figures are printed right in their results.³

Enclomiphene is not side-effect-free

You’ll read that enclomiphene "avoids estrogenic side effects." The clinical and regulatory evidence does not support that promise.⁹

FDA’s 2022 review identified hot flushes, headache, and other adverse events in enclomiphene research. It also flagged cardiac and clot-related events, raised estradiol, increased prostate-specific antigen (PSA), and increased hematocrit. Those reports do not prove the drug caused every event, but they rule out describing isolated enclomiphene as risk-free.⁹

For clomiphene, we have an FDA-approved product label, though its clinical-study adverse-event table comes from women treated for ovulatory dysfunction—not men treated for low testosterone. It reports hot flushes in 10.4% and visual symptoms in 1.5%, with a listed denominator of 8,029; the label notes possible duplicate reports. Different population, so read it as context rather than as your odds.¹

One thing to take seriously regardless of which drug: any new vision change—blurring, spots, flashes—is a call-your-prescriber-today event, not a wait-and-see. Clomiphene labeling warns that visual problems can be prolonged and potentially irreversible and calls for prompt eye assessment; blurred vision also appears in the enclomiphene safety review. Sudden vision loss needs emergency assessment.¹⁹

---

Which is better for fertility: enclomiphene or clomiphene?

Both can raise the body’s own hormone signals rather than replace testosterone from outside, which is why clinicians consider them when fertility matters. Neither drug guarantees fertility, and comparative evidence has not established a reliable pregnancy advantage. If you’re trying to conceive now, this belongs with a urologist or reproductive urologist rather than a subscription.⁸⁹

Start with the fact that makes this whole category exist.

Testosterone you take from outside your body can suppress the hormone signals that drive sperm production. The Endocrine Society recommends against starting testosterone therapy in men planning fertility in the near term. The ASRM-hosted AUA/ASRM male-infertility guideline also advises against testosterone monotherapy for a man interested in current or future fertility.⁶⁸

Spermatogenesis is the process of making sperm. It depends on FSH and on testosterone made inside the testicles. Exogenous testosterone can suppress the signals and reduce that local testosterone production. SERMs can stimulate those signals, but the cause of infertility still matters.⁸

What the AUA/ASRM guidance actually says about SERMs

The AUA/ASRM male-infertility guideline’s ASRM-published summary says clinicians may use aromatase inhibitors, hCG, SERMs, or a combination in infertile men with low serum testosterone. That is a Conditional Recommendation with Evidence Level Grade C. The same guidance says SERM benefits for unexplained infertility are limited compared with assisted reproduction.⁸

These alternatives are not interchangeable with TRT—or with each other. FDA-approved hCG products have selected male indications, including certain cases of hypogonadotropic hypogonadism. That does not give enclomiphene an approval or make hCG a universal infertility treatment.⁹

Conditional and Grade C means "reasonable to consider," not "proven." We'd rather you know that than believe a guideline said something stronger.

The pregnancy report, and how to read it

The Kassab 2023 conference report is titled Enclomiphene Is Associated With Higher Pregnancy Rates When Compared to Clomiphene in Infertile Men With Low Testosterone. Its publication record is verifiable, but its full methods and results were not accessible for this review. We therefore do not publish its reported percentages as verified comparative estimates or use them to choose a drug.⁴

That distinction matters. A conference report is not the same as a full-length study report, and an association is not proof that the drug caused the difference. A pregnancy percentage also needs the denominator, follow-up, partner factors, and any other fertility treatment to be meaningful.

Do not read a study’s pregnancy percentage as your odds. It describes a selected group, not your individual chance of pregnancy.

Separately, the Miami study found total motile sperm count improved significantly on enclomiphene and not on clomiphene—but when the two groups were compared directly against each other, the difference wasn’t statistically significant. A change that reaches significance in one group but not the other is not proof that the groups differ.²

The honest recommendation here

If you and your partner are actively trying to conceive, please don't pick a medication off a comparison article. Ask for a semen analysis. Get the cause of your low testosterone identified. A urologist or reproductive urologist can evaluate this, and neither of these drugs replaces that evaluation.⁸

There is no affiliate link in this section. There shouldn't be. This is a specialist conversation and we'd be doing you a disservice by making it anything else.

---

Is enclomiphene FDA-approved? Is clomiphene?

Clomiphene has FDA-approved drug products for ovulatory dysfunction in women who want to become pregnant; using an approved clomiphene product to treat male low testosterone is off-label. Enclomiphene has no FDA-approved product. The enclomiphene offerings reviewed here involve compounding, which is a different regulatory category—not off-label use of an approved enclomiphene drug.¹¹⁶¹¹

Three different ideas get blurred together constantly here. Separating them is most of the work.

1. An FDA-approved drug product. The FDA reviewed a manufacturer's evidence on safety, effectiveness and manufacturing quality, and approved that specific product. FDA-approved clomiphene products have this. Enclomiphene does not.¹¹⁶

2. An FDA-approved indication. What the label says the drug is for. Clomiphene's approved indication is ovulatory dysfunction in women who want to become pregnant. Low testosterone in men is not on that label.¹

3. Off-label prescribing. A clinician prescribing an FDA-approved drug for a use outside its approved labeling. FDA explains that clinicians generally may do this when medically appropriate; specialty guidance discusses selected male uses of SERMs. That is not a blanket endorsement for every man with a low test result.¹²⁸

So: an FDA-approved clomiphene product used for male low testosterone is off-label use of an approved drug. A compounded clomiphene product is still an unapproved compounded preparation.¹¹¹

Enclomiphene is something different, and the word "off-label" doesn’t quite fit it. Off-label means an approved product used for an unapproved purpose. Enclomiphene has no approved product to be off-label from. A pharmacy-prepared enclomiphene product is compounded, not FDA-approved.¹⁶¹¹

What "compounded" means and doesn't mean

Compounding means preparing or altering a drug to meet a patient’s needs. Section 503A and Section 503B set different federal conditions for qualifying compounding activities; 503A generally centers on identified-patient prescriptions, while 503B covers registered outsourcing facilities. Neither is blanket permission to compound any substance or a substitute for drug approval.¹¹¹³³⁸

Compounded does not mean fake. It also does not mean FDA-approved.

In practice, for enclomiphene, it means:

• No FDA-approved enclomiphene drug label
• No approved prescribing information for a standalone enclomiphene product
• No FDA premarket approval of the finished compounded preparation’s safety, effectiveness, and quality
• A need to check the actual pharmacy, formulation, labeling, and counseling—not assume that every compounded version is the same¹¹

Hone Health discloses on its enclomiphene page that its product is compounded and not FDA-approved. Its clomiphene page also carries a compounded-product disclosure. That second detail is easy to miss: choosing the clomiphene name at Hone does not, by itself, mean you are choosing an FDA-approved retail product.²³²²

The two-list confusion, cleared up

Two different FDA documents are often treated as if they were the same list: the final 503A Bulks List and the Category 1 substances-under-evaluation list. Being on the second is not approval or inclusion on the first.¹³

On June 8, 2022, FDA proposed that enclomiphene citrate not be added to the final 503A Bulks List, and the Pharmacy Compounding Advisory Committee voted 8 against and 4 in favor of inclusion. Separately, FDA’s May 14, 2026 nominated-substances list still includes enclomiphene citrate in Category 1—bulk drug substances under evaluation.¹⁰¹⁴

Those documents answer different questions. Category 1 can place a substance within FDA’s interim enforcement policy when all applicable conditions are met; it is not FDA approval, final-list inclusion, or blanket permission for every compounder or product. The advisory vote was not itself a ban. A 503A list entry also does not establish eligibility for 503B outsourcing.¹³

The practical distinction: an FDA-reviewed substance, an FDA-approved product, and a product compounded under an interim policy are three different things. Ask which one the provider is describing.

Where the medical societies land

In February 2026, the British Society for Sexual Medicine published a position statement on enclomiphene in the World Journal of Men’s Health. Its authors declared no conflicts of interest, but the listed affiliations include Menwell Ltd, trading as Voy, Manual, and H3 Health. A no-conflict declaration should not be rewritten as “no commercial affiliations.”¹⁵

Their position, in summary: enclomiphene may be considered in selected men with hypogonadism, including some with fertility concerns or intolerance of other treatment formats. But they do not recommend routine use outside specialist settings. They advise management by experienced clinicians, ideally within research frameworks, with counseling about its unlicensed status in the UK.¹⁵

The statement also describes enclomiphene as unapproved by the FDA and EMA and reports that its development program was discontinued in 2021. That history does not establish whether any confidential new application has since been submitted.¹⁵

There is a more important regulatory point than the development timeline. FDA’s review describes concerns about whether the trials demonstrated meaningful clinical benefit, not just higher testosterone. The review also identified safety concerns. Enclomiphene’s lack of approval is not simply a paperwork inconvenience.⁹

How do prescribing rules differ from testosterone’s?

Clomiphene and enclomiphene are prescription medications, not over-the-counter supplements; they are not federally scheduled like testosterone. Testosterone is Schedule III in the United States. As of this review, DEA’s fourth temporary extension allows qualifying controlled-substance telemedicine prescribing without a prior in-person visit through December 31, 2026, subject to the rule’s conditions and other federal and state requirements.¹⁶¹⁹²⁰

That's a paperwork difference, not a safety one. Don't let anyone turn "easier to prescribe" into "safer to take."

---

Who should not take enclomiphene or clomiphene?

Both drugs depend on a hormone system that can respond; abnormal LH or FSH needs interpretation, not self-selection from a chart. Athletes and service members need the relevant medical and rules review, not a blanket assumption that a prescription makes use permitted or impossible. A single low testosterone reading is not a diagnosis of hypogonadism.⁶⁸¹⁶¹⁸

If you’re in one of these groups, clinical evaluation comes before the cost and provider comparison. It may change whether either medication belongs in your plan at all.

If your LH and FSH are already high

There are two broad patterns of low testosterone.

Secondary hypogonadism means a problem at the hypothalamus or pituitary contributes to low testosterone. LH and FSH may be low or inappropriately normal. Some men have a system that responds to stronger signaling; others need treatment of a specific cause or a different therapy. Low or normal LH alone does not establish SERM eligibility.⁶⁸

Primary hypogonadism means the problem is mainly at the testicles. LH—and often FSH—may be high because the brain is already sending a stronger signal. Turning up that signal may not produce an adequate response; these results call for clinical interpretation rather than a promise that either SERM will solve the problem.⁶⁹

That is why the cause of low testosterone matters more than an advertisement for one molecule. A provider’s willingness to prescribe is not a substitute for that evaluation.⁶

If you don’t know what your LH and FSH mean, ask your clinician before picking between these drugs. They help distinguish causes of low testosterone; they are not a self-diagnosis or a substitute for the rest of the assessment.⁶

If you're tested for competition or serve on active duty

The 2026 WADA Prohibited List includes clomifene under anti-estrogenic substances in section S4; the category also covers related SERMs. A legitimate prescription does not itself authorize use under sport rules. The athlete must check the applicable therapeutic-use exemption requirements.¹⁷

For NCAA athletes, hormone and metabolic modulators require a medical exception approved before participation under the NCAA’s stated process. Work through the team clinician and athletics compliance staff.¹⁸

For service members, DoD’s Operation Supplement Safety program advises speaking with a military healthcare provider about whether either drug may be used and ensuring any prescription is documented in the military health record. A prohibited-ingredient list is not, by itself, proof that every military prescription is forbidden.¹⁶

If nobody has confirmed you have low testosterone

Diagnosing hypogonadism takes symptoms or signs that fit, plus consistently low testosterone confirmed with appropriate repeat early-morning testing using reliable assays. The Endocrine Society recommends repeat morning fasting total testosterone testing; its July 2026 statement again calls for at least two early-morning fasting tests.⁶⁷ Testosterone swings during the day and from week to week. One number from one afternoon draw is not a diagnosis.

We can't interpret your labs and we won't try. Neither should a symptom quiz.

When do you need a more complete clinical assessment?

• Very low testosterone with no clear explanation
• Signs pointing to pituitary or testicular disease
• A history of breast or prostate cancer
• High hematocrit (hematocrit is the share of your blood made of red blood cells)
• Untreated severe sleep apnea
• A recent heart attack or stroke
• Liver disease, a history of blood clots, or uncontrolled thyroid or adrenal disease
• Any new vision change

These findings do not all mean the same thing, and they are not a single contraindication list for both drugs. For example, clomiphene labeling specifically contraindicates liver disease or a history of liver dysfunction and certain uncontrolled endocrine disorders. A clinician may need an examination, additional testing, or specialist referral before considering hormone treatment.¹⁶⁹

If you have chest pain, trouble breathing, or another urgent symptom, seek urgent or emergency care. Don't route that through a telehealth form.

---

What do enclomiphene and clomiphene actually cost?

The real comparison is the complete care cost, not a pill price or an assumed 30-day supply. Current published examples show different membership fees, testing pathways, and even conflicting enclomiphene starting prices within one provider. An FDA-approved retail product, a compounded single-agent product, and a multi-drug blend are not equivalent purchases.^21242531

What we could reproduce on September 21, 2026

We could not reproduce a location-specific eleven-pharmacy quote for identical generic clomiphene. Without a saved location, product selection, coupon terms, and dispensing quote, a nationwide price spread would not be reliable.

Sources checked September 21, 2026. Provider figures are provider-stated; the GoodRx figure is an advertised coupon listing, not a completed pharmacy transaction.^{212425233132343536}

Thirty tablets is a quantity, not a treatment schedule. The prescriber determines how long a prescription lasts. The strength and quantity above identify the price listing; they are not a recommended dose.

At Hone Plus’s published starting prices, the difference between the two medications is $4 a month. On its Premium help page, the listed difference is $5. Those figures do not establish that the same difference applies to every prescription or that drug choice should be based on price.²⁴²⁵

Before you refill anything, check the cash and insured price of the same prescribed product, strength, and quantity at several pharmacies near you. Confirm whether you are comparing a commercial FDA-approved product with a compounded one. A cheaper quote is useful only if it is for the medicine your clinician actually prescribed.

What a full year actually costs

Monthly medication price leaves out the cost of access and monitoring. Here is a 12-month published-price model, not a claim that every required expense is included. It uses the initial fee plus 12 monthly equivalents of the applicable recurring charges, with no price changes. Actual billing and supply periods differ, as explained below.

Reproduce the arithmetic: initial fee + 12 × (membership + medication). Example: Hone Plus clomiphene is $45 + 12 × ($135 + $38) = $2,121. These are our calculations from the cited published inputs, not provider guarantees.^{2425233132343536}

For Taurus, $49 + (12 × $149) = $1,837; adding 12 × $17.99 gives $2,052.88, but the fee’s applicability and billing period are unresolved. Male Excel’s two advertised medication-price scenarios produce $2,427 and $2,727 before shipping. Its medication is billed in 60-day supplies. Twelve 30-day supplies—or six 60-day supplies—cover 360 days, so a calendar-year quote also needs the actual refill and charge dates.³²³⁴³⁶

*Published inputs checked September 21, 2026. Both Hone tiers list follow-up consultations, included monitoring, and shipping, but the exact testing plan matters. Male Excel’s terms allow additional shipping, handling, taxes, and price changes; its subtotal is not an all-in guarantee.*²⁴²⁵³³

Hone Basic is not the low-cost hormone-treatment option shown in some comparisons. Its current medication catalog places clomiphene and enclomiphene in Plus and Premium, not Basic.²⁶

An unanswered cost matters more than a neat total. Hone’s tier pages label confirmatory testing “TRT patients only,” while its membership FAQ also mentions other hormone-based treatments. We could not resolve from those pages whether an individual SERM patient would need a separately charged repeat test. Ask how the clinician will confirm low testosterone and what that will cost; “not TRT” is not a reason to diagnose from one result.^2425276

Notice that membership—not just the molecule—changes the modeled total. The current Plus inputs are lower than Premium’s; that does not make Plus the right choice if its state availability, testing pathway, or clinical scope does not fit you.²⁴²⁵²⁸

So what should a membership actually buy you beyond the medication?

Access to clinical evaluation, appropriate follow-up, and a clear plan—not a promise that someone will prescribe what you ask for.

A clinician may decide a SERM is not appropriate or may refer you to someone with more experience in male hormone or fertility care. If your primary care clinician does not prescribe one, that does not leave a subscription as your only option. A local urologist, reproductive urologist, or endocrinologist may be the better care route.⁶⁸

If you haven’t had that conversation yet—have it first. Ask about the full cost of evaluation and follow-up, including insurance coverage where applicable, before assuming either local or online care will be cheaper.

When both molecules need to stay on the table

Hone Health’s current Plus and Premium materials list both clomiphene and enclomiphene. That makes it an option to investigate when both treatments need to stay in the clinical discussion. It is not proof that Hone is the only provider offering both, that either is right for you, or that switching is guaranteed.²⁶

Affiliate disclosure: TRT Provider Guide has disclosed commercial relationships with Hone Health, Male Excel, and Taurus Meds. Those relationships are not evidence that any treatment is right for you. The links here point to provider information and our research, not a promise of a prescription. Read our affiliate disclosure.

Compare Hone’s published membership plans and included services →

The help page lists current Plus prices, services, and links to the other tiers. Confirm your state, exact medication, repeat-testing plan, pharmacy, and final charges before paying. A prescription is not guaranteed.

---

Where can you actually get either one?

An appropriately licensed clinician may prescribe commercial clomiphene off-label when it is medically appropriate. Compounded treatment can involve a local prescriber and pharmacy as well as telehealth; a subscription is not the only care route. Before paying anyone, confirm in writing which molecule you’re getting and what else is in the capsule.¹²¹¹

That last sentence isn't generic advice. Here's why we wrote it.

Our one damaging admission

TRT Provider Guide has a disclosed commercial relationship with Male Excel. So this needs saying plainly.

Male Excel’s advertised Triclozene is not a stand-alone SERM. Its product page describes a blend of enclomiphene citrate and thyroid-related medications. Its separate cost page instead names clomiphene citrate, thyroid, and selenomethionine. Those descriptions do not establish one consistent ingredient list for the prescription a patient would receive.³¹³²

The product page’s safety section discusses desiccated thyroid containing T4 and T3, warns against use for weight loss, and says that thyroid product has not undergone FDA therapeutic-equivalency testing. That footer is not a verified ingredient-and-strength label for Triclozene. Ask for the complete prescription and dispensing pharmacy’s label rather than inferring the blend from general safety text.³¹

If your clinician is considering a single SERM, Hone lists separate clomiphene and enclomiphene offerings, both described as compounded on its product pages. That is a closer product comparison than a thyroid-containing blend, but the exact prescription and pharmacy still need confirmation. For an FDA-approved commercial clomiphene product, discuss the retail-pharmacy care route instead.²²²³¹

The product page advertises $99 for the home hormone test and consultation, $95 a month for medication, and $99 a month for membership. But Male Excel’s cost page also lists Triclozene at $120/month, with medication billed in 60-day supplies and shipping extra. That is a price discrepancy to resolve—not one flat, verified all-in price.³¹³²

The page also advertises no contracts and the ability to pause or cancel anytime. Its terms separately provide for recurring billing and say sales and subscription fees are nonrefundable unless stated otherwise in writing. Canceling future care is not the same as getting a refund for a charge already made.³¹³³

Extra prescription ingredients need a clinical reason, not a convenience argument. Ask your prescriber whether you have a thyroid condition that calls for treatment and why each ingredient belongs in your plan. A simple bill does not make a multi-drug prescription the better choice.

And one more reason to get it in writing

While checking Male Excel’s Triclozene page in September 2026, we found clomiphene in its page title and enclomiphene in its headline and body copy. The cost page adds a visible clomiphene description and a different ingredient list. The mismatch is not just hidden text.³¹³²

We cannot tell from those pages which description applies to a new prescription or why they differ. We did not contact Male Excel to resolve the discrepancy, and we have not inspected a dispensed bottle.

On a decision that comes down to which molecule, don’t rely on a product name alone. Ask the provider, and get the answer in writing, before your card is charged. That goes for every provider on this page.

Before you pay anyone: 8 questions

Print this. Send it as a message during intake. The answers will tell you more about a provider than any review.

1. Which molecule is in this product — clomiphene citrate or enclomiphene citrate?
2. What else is in the capsule? Some products are blends containing other active medications.
3. Is it compounded, and which pharmacy makes it? Ask for the name and the state.
4. What will I pay in month 13, after any introductory or commitment pricing ends? Get the date and the amount.
5. What lab work is included, how often, and what do repeat tests cost if they're not?
6. Will you check my LH and FSH before starting? Ask how the clinician will establish the cause of low testosterone and whether existing results are sufficient.
7. Will you check estradiol while I'm on treatment, and what would make you change the plan?
8. How do I cancel, how much notice is required, and how do I get copies of my medical records?

Get the clinical answers from the prescriber and the medication details from the dispensing pharmacy. Keep the written price, cancellation terms, and records-access instructions. An unanswered question is a reason to pause payment, not a reason to assume the most favorable answer.

Before considering a multi-drug blend

You’ve seen the evidence, the disqualifiers, the published costs, and the formulation mismatch. Before considering Triclozene, ask Male Excel to resolve the exact molecule, all added ingredients, dispensing pharmacy, applicable price, and follow-up plan in writing. This page does not establish that its blend is the right treatment for you.

Read Male Excel’s published Triclozene description and fees →

Compare it with the separate cost page and terms. Confirm the patient’s state and any visit requirement with the provider. A consultation does not guarantee a prescription.

What about Taurus Meds?

Taurus Meds’ current enclomiphene page advertises $149/month after a $49 test-and-review offer. Its general terms also contain a $17.99-per-billing-period membership fee unless otherwise stated at purchase. The pages do not settle whether that fee applies to this particular offer.³⁴³⁵³⁶

The product page also lists anastrozole as included, without clearly resolving whether it is a separate option or part of every patient’s plan. Before treating this as plain enclomiphene, ask which medicines will actually be prescribed. Do not treat its testosterone-based benefit claims as proof of enclomiphene outcomes.³⁴

The published cancellation policy requires 72 hours’ notice before billing and restricts cancellation refunds; its terms exclude refunds for blood work and shipped medication. Those limits matter more than a money-back badge. Our Taurus Meds enclomiphene guide covers the offer separately; this comparison does not rank it as a winner.³⁷³⁶

What still needs a patient-specific answer?

Our editorial conclusion: the drug comparison does not produce a provider winner. For a single-agent discussion, confirm a single-agent prescription; for current infertility, use fertility-focused care; for a blend, require a clinical reason for every additional ingredient.

---

What did we actually verify?

We checked public documents, not patient care delivered to us. The tables distinguish published study results, provider-stated offers, and our calculations; they do not imply that we enrolled, tested a medicine, verified a patient’s clinician, or contacted support.

What we actually verified — September 21, 2026

Read and checked against the source:

• The Thomas 2023 and Saffati 2024 full reports, including their tables, statistical comparisons, limitations, and disclosures. The Kassab 2023 meeting-abstract record was located, but its full numerical results could not be independently checked.²³⁴
• FDA’s clomiphene labeling, enclomiphene advisory materials and meeting minutes, current nominated-substances list, and compounding explanation.^19101411
• Endocrine Society guidance and its July 2026 statement; the ASRM-hosted AUA/ASRM male-infertility guidance; the 2025 randomized-trial meta-analysis; and the BSSM 2026 position statement.⁶⁷⁸⁵¹⁵
• Current official Hone membership, medication, state, monitoring, and pharmacy-information pages; Male Excel’s product, cost, and terms pages; and Taurus’s product, test, terms, and refund pages.^{26282931323334353637}
• The GoodRx brand-Clomid listing, rather than an unrecorded local pharmacy transaction; and the arithmetic behind the published-price models.²¹
• DEA’s scheduling and current telemedicine extension, WADA’s 2026 list, NCAA medical-exception instructions, and DoD’s Operation Supplement Safety guidance.^1920171816

Provider-stated, not independently confirmed: delivery of promised services; the preparation a particular patient would receive; the actual dispensing pharmacy; patient-specific clinician credentials and access; and final charges after the clinical assessment. No provider’s treatment-outcome claims are evidence for this comparison.

What we could not establish: a randomized enclomiphene-versus-clomiphene trial; overall safety superiority; a reliable comparative pregnancy rate from the inaccessible meeting abstract; a reproducible eleven-pharmacy generic-price grid; or a complete individual first-year bill, including all necessary tests and refills. Unknown charges are not zero.

Two notes on sourcing. First, the Saffati report discloses industry relationships for two authors. The BSSM authors declare no conflicts, while the paper also lists commercial healthcare affiliations. Neither a disclosure nor its absence determines whether a result is sound; the study design and data still need scrutiny.³¹⁵

Second, there are no patient testimonials on this page, and that’s deliberate. A testimonial cannot establish a drug’s safety, effectiveness, or fertility outcomes. The evidence tables show the study results and the limits that a success story cannot resolve.

This page is editorial research by TRT Provider Guide, the independent decision resource for testosterone replacement therapy care. It has not been clinically reviewed. Our full process is published in How We Review TRT Providers, which separates verified facts, provider-stated facts, customer-experience signals and editorial conclusions, and calculates complete cost instead of repeating a teaser price. Where a complete cost cannot be established, we show the known inputs and the missing charges rather than invent a total.

Read our editorial standards, privacy policy, and corrections process.

---

Frequently asked questions

Neither drug has a proven overall advantage for every man. The answers below separate drug identity, evidence, product approval, and clinical suitability rather than treating them as one question.¹²³

Is enclomiphene the same as clomiphene?

No, but they’re closely related. Clomiphene citrate is a mixture containing two geometric isomers—enclomiphene and zuclomiphene. Enclomiphene is one component isolated and used alone. FDA-approved clomiphene products exist, but male use is off-label; compounded clomiphene is not itself FDA-approved. Enclomiphene has no FDA-approved drug product.^1121116

Is enclomiphene better than Clomid for low testosterone?

Not established. The two full comparative reports checked here did not find a statistically significant between-treatment difference in testosterone change. One reported fewer documented adverse effects with enclomiphene. Neither was randomized, and no randomized head-to-head trial was identified in this review.²³

Does enclomiphene raise estrogen?

It can. Thomas reported a significant rise in estradiol within its enclomiphene group, but the difference in estradiol change between treatments was not statistically significant. Saffati reported a decrease after men switched to enclomiphene. Different designs and baselines matter; neither result establishes that enclomiphene avoids estrogen-related problems.²³

Why isn’t enclomiphene FDA-approved?

FDA’s 2022 review records a 2015 Complete Response Letter rather than approval and describes concerns about trial design, meaningful clinical benefit, and safety. The advisory committee later voted against inclusion on the final 503A Bulks List; that was not a drug-approval decision. Its continued Category 1 status under the interim compounding process is also not approval.⁹¹⁰¹⁴

Is compounded enclomiphene safe?

There is no blanket safety guarantee. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing. Whether a preparation may lawfully be compounded depends on applicable requirements. Ask about the exact ingredients, pharmacy, evidence, monitoring, and adverse effects—not just whether it is “compounded.”¹¹¹³

Is clomiphene cheaper than enclomiphene?

It can be, but compare the actual prescription and full care costs. Hone’s published starting medication prices differ by $4/month in Plus and $5/month on its Premium help page; membership and testing are separate considerations. A GoodRx listing for 30 tablets is not automatically a monthly cost or a substitute for a local dispensing quote.²⁴²⁵²¹

Can I take clomiphene and enclomiphene together?

Clomiphene already contains enclomiphene. The evidence reviewed here does not establish a benefit from adding isolated enclomiphene to it. Do not combine or switch prescription medicines on your own; ask the prescriber to explain the reason for every ingredient in a proposed plan.¹²³

How long do they take to work?

Studies assess hormone changes over weeks to months; a laboratory rise is not a promise of symptom improvement on a fixed schedule. Your prescriber sets the monitoring plan based on the diagnosis, symptoms, fertility goals, and treatment. Hone’s published Plus SERM schedule, for example, lists checks at months 3, 6, and 12—not a universal rule for either drug.⁵²⁹

Will either one shrink my testicles?

These drugs stimulate hormone signaling rather than suppressing it in the same way as testosterone supplied from outside the body. That explains their role in fertility-conscious care, but it does not justify a guarantee about testicular size or fertility. A new change in testicular size, pain, or swelling needs clinical assessment.⁸⁹

Is enclomiphene a form of TRT?

No. Testosterone replacement therapy supplies testosterone from outside your body. Enclomiphene and clomiphene are SERMs that prompt your body to make more of its own. They are not interchangeable with TRT, and they aren’t a “natural” version of it.⁸⁹

Should I take a SERM instead of testosterone?

That depends on the cause of your low testosterone, your fertility plans, your labs and your medical history. There’s no universal answer. Clinical evaluation comes before choosing a drug or provider; neither this article nor a symptom quiz can establish which treatment fits.⁶⁸

Can women take enclomiphene?

Enclomiphene has no FDA-approved drug product or approved indication for women. It has been studied historically for follicular development and ovulation, so “never studied in women” is incorrect. Clomiphene is FDA-approved for certain women with ovulatory dysfunction who want to become pregnant; this male-treatment comparison is not guidance for choosing an ovulation medicine.⁹¹

---

Where should you go from here?

The next step is to confirm the diagnosis, compare the exact products and complete costs, and ask a clinician which tradeoff fits your goals. The marketing version of this question has a clean answer. The evidence version doesn’t establish one winner for everyone.⁶²³

What we can tell you with confidence:

• Ask your clinician what your LH and FSH mean and whether further evaluation is needed
• Check your prescription price at more than one pharmacy
• Ask every provider which molecule is in the bottle, in writing
• If you're trying to conceive now, start with a urologist, not a subscription

Want to go deeper on the older, better-documented option? Read our clomiphene review for men.

Still not sure which TRT care route fits you? Use our free Find My TRT Path tool.

---

*This page is educational information, not medical advice. It cannot diagnose low testosterone, interpret your lab results, or tell you which medication is right for you. Testosterone is a Schedule III controlled substance in the United States and requires a valid prescription; clomiphene and enclomiphene also require a prescription. Prescribing rules, provider prices, availability, and compounding policies can change. If you’re experiencing chest pain, difficulty breathing, sudden vision loss, or another urgent symptom, seek emergency care.*¹⁹¹⁶¹

TRT Provider Guide is not a clinic, pharmacy, laboratory, drug manufacturer, insurer or medical practice.

---

---

Sources

1. DailyMed. Clomid (clomiphene citrate) prescribing information, updated January 31, 2025. See Description; Indications and Usage; Contraindications; Visual Symptoms; Adverse Reactions; and product information. Checked September 21, 2026.
2. Thomas et al. Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study. Cureus, July 2023. Full report checked through the author-uploaded article, including the within-group and between-group comparisons. Checked September 21, 2026.
3. Saffati et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Translational Andrology and Urology. 2024;13(9):1984–1990. DOI: 10.21037/tau-24-238. See Tables 1–4, Results, Limitations, and Conflicts of Interest. Checked September 21, 2026.
4. Kassab et al. MP43-13: Enclomiphene is associated with higher pregnancy rates when compared to clomiphene in infertile men with low testosterone. Journal of Urology, 2023 meeting abstract. The title and publication record were checked through its bibliographic record and Baylor’s meeting listing; full numerical results were not independently accessible in this review. Checked September 21, 2026.
5. Hohl et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025;69(5):e250093. Full text checked through the author-uploaded report. Checked September 21, 2026.
6. Endocrine Society. Testosterone Therapy for Hypogonadism: Clinical Practice Guideline, 2018 guideline and current issuer summary. Diagnosis, repeat morning fasting testing, LH/FSH, further evaluation, and fertility recommendations. Checked September 21, 2026.
7. Endocrine Society. Statement on Testosterone Replacement Therapy, July 16, 2026. See diagnosis, reversible contributors, and testing-quality recommendations. Checked September 21, 2026.
8. AUA/ASRM. Diagnosis and Treatment of Infertility in Men: Guideline Part II, Fertility and Sterility, January 2021, issuer-hosted summary. See page 64, statements 38–42 and the accompanying discussion. This citation identifies the published version actually reviewed. Checked September 21, 2026.
9. FDA. Pharmacy Compounding Advisory Committee slides, June 8, 2022. Enclomiphene review: pharmacology and pharmacokinetics; clinical studies; adverse events and safety concerns; regulatory history; historical studies of ovulation; and FDA staff recommendation. See PDF pages 15–49. Checked September 21, 2026.
10. FDA. Final minutes: Pharmacy Compounding Advisory Committee, June 8, 2022. Page 7 of 8 records the enclomiphene vote: four in favor, eight against inclusion on the 503A Bulks List. Checked September 21, 2026.
11. FDA. Understanding the Risks of Compounded Drugs. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. Checked September 21, 2026.
12. FDA. Understanding Unapproved Use of Approved Drugs “Off Label”. Checked September 21, 2026.
13. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. See final-list criteria and interim enforcement-policy conditions. Checked September 21, 2026.
14. FDA. Bulk drug substances nominated for use in compounding under section 503A, updated May 14, 2026. Enclomiphene citrate appears in Category 1. Checked September 21, 2026.
15. British Society for Sexual Medicine. Position statement on clomiphene and enclomiphene. World Journal of Men’s Health, published online February 13, 2026. See affiliations, regulatory status, clinical recommendations, and declarations. Checked September 21, 2026.
16. Department of Defense, Operation Supplement Safety. Clomiphene and Enclomiphene: Drugs, Not Dietary Supplements, January 12, 2026. Prescription status, military medical review, and sports restrictions. Checked September 21, 2026.
17. World Anti-Doping Agency. 2026 Prohibited List, section S4.2, anti-estrogenic substances. Checked September 21, 2026.
18. NCAA. Medical Exceptions. See prior approval for hormone and metabolic modulators. Checked September 21, 2026.
19. DEA Diversion Control Division. Controlled Substances: Alphabetical Order. Testosterone is listed in Schedule III. Checked September 21, 2026.
20. DEA. DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care, December 31, 2025. Fourth temporary extension through December 31, 2026, subject to applicable conditions. Checked September 21, 2026.
21. GoodRx. Clomiphene/Clomid price listing. Brand Clomid, 50 mg, 30 tablets; advertised coupon price, not a confirmed local dispensing quote. Checked September 21, 2026.
22. Hone Health. Clomiphene product page. Starting price and compounded-drug disclosure. Provider-stated; checked September 21, 2026.
23. Hone Health. Enclomiphene product page. Starting price and compounded-drug disclosure. Provider-stated; checked September 21, 2026.
24. Hone Health. Hone Plus Membership: Men’s Hormone Optimization with Labs, updated September 10, 2026. Initial test, membership, starting medication prices, lab panel, and included services. Provider-stated; checked September 21, 2026.
25. Hone Health. Hone Premium Membership: Full Clinical Insight for Men, updated September 9, 2026. Initial test, membership, medication prices, confirmatory testing, and inclusions. Provider-stated; checked September 21, 2026.
26. Hone Health. Medications Available for Men, updated September 9, 2026. Clomiphene and enclomiphene are listed for Plus and Premium. Provider-stated; checked September 21, 2026.
27. Hone Health. Membership Frequently Asked Questions, updated September 4, 2026. Billing, confirmatory testing, and cancellation. Provider-stated; checked September 21, 2026.
28. Hone Health. Service Availability by State (2026), updated September 4, 2026. Separate Plus and Premium lists. Provider-stated; checked September 21, 2026.
29. Hone Health. Men’s Plus HRT Lab Testing Schedule for Clomiphene and Non-TRT Therapies, updated September 4, 2026. Provider-stated; checked September 21, 2026.
30. Hone Health. Where Does Hone Get Its Pharmaceuticals and Supplements?, updated September 4, 2026. Pharmacy-network description, not confirmation of a particular patient’s dispensing pharmacy. Checked September 21, 2026.
31. Male Excel. Triclozene product page. Product title/body, advertised blend, pricing, and safety disclosures. Provider-stated; checked September 21, 2026.
32. Male Excel. Hormone treatment costs. Differing Triclozene prices and ingredient descriptions, 60-day medication billing, membership, and shipping. Provider-stated; checked September 21, 2026.
33. Male Excel. Terms and Conditions. Billing, price changes, shipping and handling, final sales, and nonrefundable fees. Provider-stated; checked September 21, 2026.
34. Taurus Meds. Enclomiphene product page. Advertised price, included services, anastrozole wording, and reused TRT claims. Provider-stated; checked September 21, 2026.
35. Taurus Meds. Testosterone blood test and consultation offer. Advertised $49 starting offer. Provider-stated; checked September 21, 2026.
36. Taurus Meds. Terms of Service. See returns, section 28’s recurring membership fee, and named pharmacy partners. Provider-stated; checked September 21, 2026.
37. Taurus Meds. Subscription Services Cancellation and Refund Policy, updated February 28, 2026. Notice deadline, billing, and refund limits. Provider-stated; checked September 21, 2026.
38. FDA. Compounding and the FDA: Questions and Answers. See who may compound, outsourcing facilities, and the distinct quality requirements under sections 503A and 503B. Checked September 21, 2026.